<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375437</url>
  </required_header>
  <id_info>
    <org_study_id>ET17-080 (RNASARC)</org_study_id>
    <nct_id>NCT03375437</nct_id>
  </id_info>
  <brief_title>RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.</brief_title>
  <acronym>RNASARC</acronym>
  <official_title>RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ignyta, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicenter, prospective cohort study aiming to describe molecular profiles
      of soft tissue sarcoma (STS) with complex genomic profiles in particular to assess the
      incidence of NTRK1/2/3, ROS1 or ALK gene fusions to direct such patients through an ongoing
      clinical trial with entrectinib when appropriate. An exploratory translational program is
      also correlated to this trial in order to analyse immune gene expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following inform consent form (ICF) signature, a formalin-fixed and paraffin-embedded (FFPE)
      tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for
      all enrolled patients and centralized at the biological resources platform of the Centre Léon
      Bérard.

      At reception, a central pathological review will be performed to confirm if quality and
      quantity of material is acceptable: all tumor sample should present at least 20 % (ideally 30
      %) of tumor cells and have a surface area &gt; 5 mm2 (optimal condition is a surface area of
      5-25 mm2). If the quality and quantity of tumor sample do not meet the standards, patients
      will be considered as &quot;screening failure&quot;. If standards are met, inclusion will be confirmed
      and molecular screening will be initiated as well as the translational research program.

      The molecular screening to detect NTRK1,2,3, ROS1 or ALK gene rearrangements will be a
      two-step process, consisting of :

        1. First, immunohistochemistry (IHC) assay to detect protein expression of TRKA/B/C
           (encoded by NTRK1,2,3), ROS1 or ALK. Only positive IHC samples will continued the 2nd
           step of molecular screening. Negative IHC patients do not require further NTRK, ROS or
           ALK gene rearrangement testing; however tumor samples will be further used for
           additional translational research program presented in Section VII and data about the
           clinical evolution of these patients will be collected

        2. Second, RNAseq analysis will be performed on positive IHC specimens to detect specific
           rearrangements in the NTRK1,NTRK2, NTRK3, ROS1 or ALK genes.

        3. Following molecular analyses, screening results will be immediately (within 24 hours)
           communicated to investigators, GSF-GETO Network and Ignyta representatives in order to
           recommend patients with NTRK1, NTRK2, NTRK3, ROS1 or ALK rearrangement for formal
           eligibility determination for potential enrolment in a clinical trial in particular with
           entrectinib (STARTRK-2; NCT02568267).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with NTRK1/2/3, ROS1 or ALK gene fusions (95% confidence interval)</measure>
    <time_frame>24 months</time_frame>
    <description>Such molecular pre-screening will allow to direct eligible patients with sarcomas harboring an NTRK1/2/3, ROS1 or ALK fusion to a clinical trial with entrectinib, when judged appropriate by the patient's treating oncologist. Depending of the molecular alterations, other therapeutic options could be envisaged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with NTRK1/2/3, ROS1, or ALK gene fusion per histological sub-types of STS with complex genomics</measure>
    <time_frame>24 months since first inclusion</time_frame>
    <description>the partitioning of STS patients with NTRK1/2/3, ROS1 or ALK gene fusions within the different STS sub-types.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical characteristics of patients with NTRK1/2/3, ROS1, or ALK gene fusion versus patients with no NTRK1/2/3, ROS1, or ALK gene fusion.</measure>
    <time_frame>24 months since first inclusion</time_frame>
    <description>Comparisons of quantitative variables will be assessed with Student t-test or Wilcoxon-Mann and Whitney test , as appropriate. Comparisons of qualitative variables will be assessed with the X2 test or the Fisher's exact test, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-cancer treatments initiated since inclusion.</measure>
    <time_frame>36 months</time_frame>
    <description>anti-cancer treatments initiated since inclusion among patients with NTRK1/2/3, ROS1, or ALK gene fusion and among patients with no NTRK1/2/3, ROS1, or ALK gene fusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) among patients with NTRK1/2/3, ROS1, or ALK gene fusion and among patients with no NTRK1/2/3, ROS1, or ALK gene fusion. It will be measured from the date of STS diagnosis to the date of death from any cause. Patients who are alive at the time of analysis will be censored at the date of last contact. OS will be estimated using the Kaplan-Meier method, and will be described in terms of medians along with the associated 2-sided 95% confidence interval (CI)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>NTRK, ROS and ALK molecular screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood and tumor samples</intervention_name>
    <description>FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.
Blood sampling for Translational Research (optional) (2*10mL EDTA)</description>
    <arm_group_label>NTRK, ROS and ALK molecular screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  I1. Male or female patients aged ≥ 12 years at time of informed consent form (ICF)
             signature.

          -  I2. Histologically confirmed diagnosis of advanced /metastatic disease STS with
             complex genomics (e.g., Leiomyosarcoma [LMS], Undifferentiated Pleomorphic Sarcoma
             [UPS], pleomorphic liposarcoma/rhabdomyosarcoma [P-LPS/P-RMS], angiosarcoma, malignant
             peripheral nerve sheath tumor [MPNST], myxofibrosarcoma, fibrosarcoma).

          -  I3. Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
             sample, with the corresponding hematoxylin and eosin stained slide and a pathological
             report:

        either a tumor archival block (less than 3 years old) or a dedicated freshly collected de
        novo biopsy performed from one accessible lesion visible by medical imaging and accessible
        to percutaneous sampling with a diameter of at least 10 mm.

          -  I4. Tumor sample meeting following quality/quantity control (QC) criteria confirmed by
             a central pathological review:

        at least 20% (ideally 30%) of tumor cells and a sample size surface area &gt; 5mm2 (ideally
        5-25mm2).

          -  I5. Patient (and legal guardians if not-emancipated minor) should understand, sign,
             and date the written voluntary informed consent form prior to any protocol-specific
             procedures performed. Patient should be able and willing to comply with study
             procedures as per protocol.

          -  I6. Patient must be covered by a medical insurance.

        Non-inclusion criteria:

          -  NI1. Patients with non-assessable tumor sample.

          -  NI2. Prior treatment with approved or investigational TRK, ROS1, or ALK inhibitors.
             Any other prior anticancer therapy are allowed with no limit of prior number of
             treatment lines.

          -  NI3. Pregnant or breast-feeding patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armelle DUFRESNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armelle DUFRESNE, MD</last_name>
    <phone>(0)4 69 85 61 47</phone>
    <phone_ext>+33</phone_ext>
    <email>armelle.dufresne@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas ISAMBERT, MD</last_name>
      <email>nisambert@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Céline CHARON BARRA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey HENNEQUIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice HERVIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie ZANETTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle DUFRESNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi BRAHMI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadège CORRADINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RAY-COQUARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier COLLARD, MD</last_name>
      <email>olivier.collard@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464.</citation>
    <PMID>27291997</PMID>
  </reference>
  <reference>
    <citation>Jain S, Xu R, Prieto VG, Lee P. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol. 2010 Apr 23;3(4):416-28. Review.</citation>
    <PMID>20490332</PMID>
  </reference>
  <reference>
    <citation>Fleitas T, Ibarrola-Villava M, Ribas G, Cervantes A. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. Cancer Treat Rev. 2016 Sep;49:57-64. doi: 10.1016/j.ctrv.2016.07.007. Epub 2016 Jul 29. Review.</citation>
    <PMID>27501018</PMID>
  </reference>
  <reference>
    <citation>Schmidt KT, Chau CH, Price DK, Figg WD. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. J Clin Pharmacol. 2016 Dec;56(12):1484-1499. doi: 10.1002/jcph.765. Epub 2016 Jun 17. Review.</citation>
    <PMID>27197880</PMID>
  </reference>
  <reference>
    <citation>Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001 Aug 28;169(2):107-14. Review.</citation>
    <PMID>11431098</PMID>
  </reference>
  <reference>
    <citation>Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature. 1982 Dec 9;300(5892):539-42.</citation>
    <PMID>7144906</PMID>
  </reference>
  <reference>
    <citation>Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986 Feb 27-Mar 5;319(6056):743-8.</citation>
    <PMID>2869410</PMID>
  </reference>
  <reference>
    <citation>Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27.</citation>
    <PMID>25264305</PMID>
  </reference>
  <reference>
    <citation>Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.</citation>
    <PMID>24670165</PMID>
  </reference>
  <reference>
    <citation>Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015 Jan;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765. Epub 2014 Dec 19. Review.</citation>
    <PMID>25527197</PMID>
  </reference>
  <reference>
    <citation>Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.</citation>
    <PMID>26216294</PMID>
  </reference>
  <results_reference>
    <citation>Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5.</citation>
    <PMID>24618336</PMID>
  </results_reference>
  <results_reference>
    <citation>Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.</citation>
    <PMID>27621408</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trial</keyword>
  <keyword>Multicenter Trial</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>ROS1</keyword>
  <keyword>ALK</keyword>
  <keyword>RNAseq</keyword>
  <keyword>entrectinib</keyword>
  <keyword>STARTRK-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

